SS-31 (Elamipretide): Mitochondria-Targeted Peptide Research in Aging and Cardiac Models

Introduction

SS-31 (also known as elamipretide, MTP-131, or Bendavia) is a synthetic tetrapeptide with the sequence D-Arg-2’,6’-Dmt-Lys-Phe-NH₂. It belongs to the Szeto-Schiller (SS) peptide family, designed to selectively concentrate within the inner mitochondrial membrane (IMM) — the site of the electron transport chain and ATP synthesis. SS-31 represents one of the most advanced mitochondria-targeted research peptides, with a mechanism of action that directly addresses the cardiolipin oxidation that underlies mitochondrial dysfunction in aging, ischemia, and metabolic disease [1].

Unlike antioxidants that scavenge reactive oxygen species (ROS) in the cytoplasm, SS-31 acts at the source of ROS production within the mitochondria, making it a mechanistically distinct tool for studying mitochondrial biology.

Molecular Characteristics and Mitochondrial Targeting

| Parameter | Value | |---|---| | Sequence | D-Arg-2’,6’-Dmt-Lys-Phe-NH₂ | | Molecular weight | ~639 Da | | Net charge | +3 (at physiological pH) | | Mitochondrial accumulation | ~1,000-fold concentration in IMM | | Primary target | Cardiolipin in inner mitochondrial membrane |

SS-31's selective accumulation in the IMM is driven by its alternating aromatic and cationic residues, which interact with the negatively charged cardiolipin-rich inner membrane. This structural feature allows SS-31 to achieve mitochondrial concentrations approximately 1,000-fold higher than cytoplasmic concentrations following systemic administration [2].

Mechanism of Action: Cardiolipin Stabilization

Cardiolipin is a unique phospholipid found almost exclusively in the IMM, where it plays essential structural and functional roles: - Stabilizing electron transport chain (ETC) complexes (particularly Complex I, III, and IV) - Maintaining the cristae structure that maximizes ETC efficiency - Supporting cytochrome c binding to the IMM (preventing its release as an apoptosis signal)

In aging, ischemia, and metabolic disease, cardiolipin undergoes peroxidation — oxidative damage that disrupts its structure and impairs ETC function. SS-31 binds directly to cardiolipin, stabilizing its structure and preventing peroxidation. This preserves ETC complex assembly, maintains mitochondrial membrane potential, and reduces electron leak that generates superoxide [3].

Research Findings in Aging Models

Skeletal Muscle and Physical Performance

One of the most compelling findings in SS-31 research is its ability to reverse age-related mitochondrial dysfunction in skeletal muscle. Siegel et al. (2013) demonstrated that a single injection of SS-31 in aged mice restored mitochondrial respiration to levels comparable to young animals within hours — a finding that challenged the assumption that age-related mitochondrial decline is irreversible [4].

In aged mice, 8-week SS-31 treatment produced: - Significant improvements in exercise tolerance and grip strength - Restoration of mitochondrial membrane potential in skeletal muscle - Reduced oxidative stress markers (4-HNE, protein carbonyls) - Improved mitochondrial morphology (reduced fragmentation) [5]

Cardiac Research

SS-31 has been extensively studied in cardiac ischemia-reperfusion (I/R) injury models. Key findings include:

- Reduced infarct size: SS-31 administered before or during reperfusion significantly reduces myocardial infarct size in rodent and large animal models - Preserved cardiac function: Improved ejection fraction and reduced ventricular remodeling following I/R injury - Mitochondrial protection: Preservation of mitochondrial morphology and function in cardiomyocytes during reperfusion stress

A landmark eLife study (2020) demonstrated that 8-week SS-31 treatment in old mice substantially reversed cardiac aging phenotypes, including diastolic dysfunction and cardiac hypertrophy — effects that persisted after treatment cessation [6].

Kidney Research

SS-31 has shown significant protective effects in models of acute kidney injury (AKI) and chronic kidney disease (CKD), where mitochondrial dysfunction in renal tubular cells is a key pathological driver. Research demonstrates reduced tubular cell apoptosis, improved GFR, and reduced fibrosis markers following SS-31 treatment in cisplatin-induced AKI models.

Comparison with Other Mitochondria-Targeted Compounds

| Compound | Mechanism | Mitochondrial Targeting | Research Stage | |---|---|---|---| | SS-31 (Elamipretide) | Cardiolipin stabilization | IMM-selective | Clinical trials | | MitoQ | ROS scavenging (ubiquinone) | Matrix-targeted | Clinical trials | | SkQ1 | ROS scavenging (plastoquinone) | Matrix-targeted | Clinical trials | | MOTS-c | AMPK activation | Mitochondrial-derived | Preclinical |

Research Applications

SS-31 is utilized in research examining: - Mitochondrial bioenergetics in aging, disease, and stress models - Cardiac ischemia-reperfusion injury and cardioprotection - Sarcopenia and age-related muscle dysfunction - Renal tubular cell biology in nephrotoxicity models - Neurodegenerative disease models where mitochondrial dysfunction is implicated

For research use only. Not for human or animal consumption.

References

1. Szeto, H.H. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 171(8), 2029–2050.
2. Zhao, K., et al. (2004). Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry, 279(33), 34682–34690.
3. Birk, A.V., et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8), 1250–1261.
4. Siegel, M.P., et al. (2013). Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell, 12(5), 763–771.
5. Hiona, A., et al. (2010). Mitochondrial DNA mutations induce mitochondrial dysfunction, apoptosis and sarcopenia in skeletal muscle of mitochondrial DNA mutator mice. PLOS ONE, 5(7), e11468.
6. Whitson, J.A., et al. (2020). SS-31 and NMN: Two paths to improve metabolism and function in aged hearts. eLife, 9, e55513.